healthevidencedigest

Tag: dermatology

  • Ebglyss Can Now Be Given Every 8 Weeks Instead of Every 4. For Patients With Moderate-to-Severe Atopic Dermatitis, That Is a Meaningful Change. Here Is What the Science Shows.

    Ebglyss Can Now Be Given Every 8 Weeks Instead of Every 4. For Patients With Moderate-to-Severe Atopic Dermatitis, That Is a Meaningful Change. Here Is What the Science Shows.

    The essentials: On June 9, 2026, the FDA approved a new maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz, Eli Lilly): one injection of 250 mg every 8 weeks (Q8W) for adults and adolescents aged 12 years and older weighing at least 40 kg (approximately 88 lbs) with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical prescription therapies. This is a new dosing regimen approval, not a new drug or new indication. Ebglyss was originally approved in September 2024 for the same population with a once-every-4-weeks (Q4W) maintenance regimen. The complete dosing schedule with the Q8W option: induction with 500 mg (two 250 mg injections) at weeks 0 and 2, then 250 mg every 2 weeks through week 16 or until adequate clinical response is achieved, followed by maintenance dosing of either 250 mg Q4W or 250 mg Q8W. What makes the Q8W approval clinically notable: Ebglyss is now the only FDA-approved biologic for atopic dermatitis that offers as few as 6 maintenance injections per year without a mandatory requirement for concomitant topical therapy from treatment initiation. No other approved AD biologic currently combines both of these features. The evidence basis: longitudinal exposure-response modeling and the Q8W ADjoin extension (NCT04392154), a 32-week open-label study evaluating Q8W and Q4W dosing in patients who had completed the 100-week ADjoin long-term study. No new safety signals were identified. No patients discontinued due to adverse events through 32 weeks. Important interpretive caveat: extension participants had already received approximately 100 weeks of lebrikizumab therapy before entering the Q8W study. The real-world applicability to newly initiating patients who transition to Q8W earlier has not been directly studied.

    Atopic dermatitis is not a rash. It is a chronic, relapsing immune-mediated inflammatory disease of the skin that affects an estimated 16 million adults in the United States, more than 10% of the adult population, and a substantially higher proportion of children. At its severe end, atopic dermatitis produces relentless itch, disrupted sleep, cracked and weeping skin, and a psychological burden documented to rival conditions such as psoriasis and chronic pain. For adults and adolescents with moderate-to-severe disease inadequately controlled by topical therapies, systemic treatments including biologics are increasingly the standard of care.

    Ebglyss (lebrikizumab), an IL-13 inhibitor, was approved in September 2024 with a once-monthly (Q4W) maintenance dosing schedule. On June 9, 2026, the FDA approved an expanded maintenance option: one injection every 8 weeks (Q8W), allowing eligible patients to reduce their annual injection burden from 13 to as few as 6 after completing induction. That numerical change from 13 to 6 injections per year is not a trivial reduction in the context of a disease that will require ongoing management for most patients indefinitely.

    This post covers what atopic dermatitis is, how IL-13 drives its pathology and why blocking it works, what the ADjoin extension data supports, what the competitive significance of the Q8W approval is, and what patients and prescribers need to know about the dosing schedule in practice.

    What Atopic Dermatitis Is and Why Moderate-to-Severe Disease Requires Systemic Therapy

    Atopic dermatitis is a chronic inflammatory skin disease driven by dysfunction in both the skin barrier and the immune system. The two abnormalities are interconnected: a defective epidermal barrier, often related to mutations in the gene encoding filaggrin, allows allergens, irritants, and microorganisms to penetrate the skin, triggering and sustaining a type 2 (Th2-skewed) immune response. The resulting cytokine cascade, dominated by IL-4, IL-13, and IL-31, drives ongoing skin inflammation, barrier disruption, and the hallmark symptom of atopic dermatitis: intense, persistent itch.

    The Th2-skewed immune response in atopic dermatitis is what has made this disease amenable to targeted biologic therapy. The first approved biologic for AD, dupilumab (Dupixent), targets both IL-4 and IL-13 by blocking the shared IL-4 receptor alpha chain. Lebrikizumab takes a more targeted approach: it binds specifically and exclusively to IL-13.

    Why moderate-to-severe atopic dermatitis requires more than topical therapy

    Topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus) are effective for mild to moderate disease but have significant limitations in moderate-to-severe disease. Long-term topical corticosteroid use carries risks of skin atrophy, striae, and hypothalamic-pituitary-adrenal axis suppression with extensive application. The emotional and logistical burden of applying topical agents to extensive, inflamed skin multiple times daily is substantial, particularly for patients with involvement of difficult-to-treat areas such as the face, neck, and skin folds.

    For patients whose disease is not adequately controlled by topical prescription therapies, systemic options including biologics targeting IL-4/IL-13 signaling (dupilumab, tralokinumab, lebrikizumab) and the JAK inhibitor class (upadacitinib, abrocitinib, baricitinib) represent the current standard. No mandatory concomitant topical therapy requirement at treatment initiation is a practical advantage for patients with extensive or difficult-to-treat distribution.

    The Science: How IL-13 Drives Atopic Dermatitis and Why Blocking It Works

    Interleukin-13 (IL-13) is a cytokine produced primarily by activated Th2 T cells, innate lymphoid cells type 2 (ILC2), and mast cells in atopic skin. It is the dominant driver of multiple pathological processes in atopic dermatitis:

    Skin barrier disruption: IL-13 suppresses the expression of filaggrin, loricrin, and other structural proteins essential for the epidermal barrier. By reducing barrier protein synthesis, IL-13 perpetuates the permeability defect that allows allergen penetration and drives the cycle of sensitization and immune activation.

    Itch: IL-13 directly stimulates sensory nerve fibers and primes skin-resident cells to release histamine and other pruritogens, contributing directly to the intense itch that is the defining symptom of atopic dermatitis.

    Inflammation: IL-13 activates keratinocytes, fibroblasts, and other skin cells to produce chemokines and adhesion molecules that recruit additional immune cells to the skin, amplifying the local inflammatory response.

    IgE production: IL-13 cooperates with IL-4 to drive B cell class switching to IgE production, the antibody class responsible for atopic sensitization.

    Lebrikizumab is a high-affinity human monoclonal antibody that binds specifically to IL-13 itself, rather than to the IL-4/IL-13 shared receptor that dupilumab targets. By capturing circulating IL-13 before it can engage its receptor, lebrikizumab blocks downstream signaling through both the IL-13Rα1/IL-4Rα heterodimer (the signaling receptor for IL-13 in skin cells) and the IL-13Rα2 decoy receptor. The high binding affinity and specificity for IL-13 means the drug does not affect IL-4 signaling, which distinguishes it from dupilumab pharmacologically, though clinical outcomes in pivotal trials have been broadly comparable in terms of efficacy endpoints.

    The structural basis for lebrikizumab’s IL-13 binding has been characterized crystallographically: the antibody binds at a distinct epitope on IL-13 that prevents both IL-13Rα1 and IL-13Rα2 engagement, explaining the completeness of its IL-13 blockade.

    The Approved Dosing Schedule: Complete and Correct

    With the June 9, 2026 approval, the complete Ebglyss dosing schedule for the approved population (adults and adolescents aged 12 years and older, weight at least 40 kg) is:

    PhaseDoseFrequency
    Induction (weeks 0 and 2)500 mg (two 250 mg injections administered at the same visit)Two doses, two weeks apart
    Maintenance (weeks 2 through 16 or until adequate response)250 mg single injectionEvery 2 weeks (Q2W)
    Maintenance (after adequate response achieved, ongoing)250 mg single injectionEvery 4 weeks (Q4W) OR every 8 weeks (Q8W) — patient and clinician choice

    The decision between Q4W and Q8W maintenance should be individualized. Patients with robust and sustained response who prefer a less frequent injection schedule are candidates for Q8W. Patients with a history of more frequent flares or less complete response may be better maintained on Q4W. This is a clinical judgment discussion between the patient and their dermatologist.

    Annual injection count summary:

    • Induction (2 visits, 4 injections total across weeks 0 and 2, plus Q2W phase)
    • Q4W maintenance: approximately 13 injections per year
    • Q8W maintenance: as few as 6 injections per year

    The ADjoin Extension Data: What Supported the Q8W Approval

    The Q8W approval was based on two complementary data sources: longitudinal exposure-response modeling and the Q8W ADjoin extension study.

    Exposure-response modeling

    The pharmacokinetic and pharmacodynamic data from the original lebrikizumab development program, including ADvocate 1 and ADvocate 2 (the pivotal Phase 3 trials), demonstrated that lebrikizumab’s long half-life and sustained IL-13 suppression at Q8W dosing supported the hypothesis that every-8-week dosing could maintain therapeutic drug levels and clinical response in patients who had achieved adequate disease control. Longitudinal exposure-response modeling provides the mechanistic rationale for the regimen; the ADjoin extension provided the confirmatory clinical data.

    ADjoin extension (NCT04392154)

    The Q8W ADjoin extension was a 32-week open-label study evaluating Q8W and Q4W dosing in adult and adolescent patients who had completed the 100-week ADjoin long-term study. ADjoin itself enrolled completers from four prior Phase 3 trials: ADvocate 1 and 2 (52-week trials), ADore (52-week trial), and ADopt-VA (16-week trial). Patients in the extension received open-label Ebglyss 250 mg, Q8W or Q4W, regardless of their prior dosing interval (Q2W or Q4W) or response status at extension baseline.

    Extension safety findings:

    • No new safety signals identified through 32 weeks of Q8W dosing
    • No patients discontinued due to adverse events through 32 weeks
    • Safety profile consistent with the established lebrikizumab dataset

    Efficacy:

    • Disease control was maintained through 32 weeks in both Q8W and Q4W dosing groups
    • Long-term data from the broader lebrikizumab program show durable disease control for up to 4 years of continuous treatment

    Dr. Peter Lio, MD, primary investigator of the ADjoin study and Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University, noted that extending maintenance dosing to every eight weeks represents an important option for patients living with moderate-to-severe atopic dermatitis.

    The important interpretive caveat

    The patients in the Q8W ADjoin extension had already completed approximately 100 weeks of lebrikizumab therapy before entering the extension. They were therefore a population with demonstrated long-term tolerability and sustained response, representing a selected, treatment-experienced group. The real-world applicability of Q8W dosing in newly initiating patients who have completed induction and transitioned earlier to Q8W maintenance has not been directly studied in a de novo population. Dermatologists should discuss this with patients: the 6-injections-per-year figure applies to patients who have achieved and maintained adequate response; the long-term profile of Q8W in newly initiated patients should be monitored as real-world experience accumulates.

    Competitive Context: Where This Places Ebglyss in the AD Biologic Landscape

    The atopic dermatitis biologic market in 2026 is the most competitive it has ever been. The approved biologics for moderate-to-severe AD include:

    DrugTargetApprovalDosing (maintenance)Mandatory topical
    Dupixent (dupilumab, Sanofi/Regeneron)IL-4Rα (blocks IL-4 and IL-13)2017 (adults); expandedQ2WNo
    Adbry (tralokinumab, LEO Pharma)IL-132021Q2W; Q4W option availableNo
    Ebglyss (lebrikizumab, Lilly)IL-132024Q4W or Q8WNo

    The Q8W approval gives Ebglyss a dosing frequency advantage over dupilumab (Q2W mandatory maintenance) and tralokinumab (Q2W standard, Q4W available for responders). Ebglyss’s Q8W maintenance option of as few as 6 injections per year, without a mandatory concomitant topical therapy requirement, is a combination not currently available with any other approved AD biologic. That distinction is commercially meaningful for Lilly and clinically meaningful for the subset of patients who are well-controlled responders and for whom injection burden influences long-term adherence.

    The practical comparison for prescribers: dupilumab has the most extensive long-term evidence base and the broadest approved indication range (including asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and prurigo nodularis in addition to AD). For patients whose primary driver is AD management and for whom injection frequency is a concern, Ebglyss’s Q8W option is now a differentiating factor worth discussing.

    Safety: What Prescribers and Patients Need to Know

    The safety profile of lebrikizumab with the Q8W dosing regimen is consistent with the established dataset from the full lebrikizumab clinical program. The most common adverse reactions (occurring in at least 1% of patients) are:

    Conjunctivitis: The most characteristic class effect across all IL-4/IL-13 pathway targeting biologics. Conjunctivitis in the lebrikizumab trials occurs at lower rates than typically reported with dupilumab, which is a clinically relevant distinction for patients who have experienced significant eye symptoms on dupilumab. Mild to moderate conjunctivitis should be assessed and treated with ophthalmic supportive care; if severe or persistent, ophthalmology consultation and discussion of dose adjustment are appropriate.

    Injection site reactions: Common, typically mild (redness, pain, swelling at the injection site), and generally not requiring discontinuation. Rotate injection sites; abdomen, thigh, and upper arm are acceptable locations.

    Herpes zoster: IL-13 pathway inhibition has a low but documented association with herpes zoster (shingles) reactivation. Patients who have not been vaccinated against herpes zoster should discuss vaccination with their dermatologist before initiating long-term biologic therapy for atopic dermatitis.

    Contraindications:

    • Hypersensitivity to lebrikizumab-lbkz or any ingredient in Ebglyss

    Live vaccines: As with all biologic therapies, live attenuated vaccines should not be administered during lebrikizumab treatment. Update all vaccines, including zoster vaccine, before initiating therapy.

    Pregnancy: The effect of lebrikizumab on a developing fetus is not fully established. Discuss contraception and pregnancy planning with patients of reproductive potential. A pregnancy exposure registry (1-800-545-6962) is available for patients who become pregnant while on Ebglyss.

    What This Means for Patients

    For patients currently on Ebglyss Q4W who are achieving good disease control, the Q8W option is now available to discuss with their dermatologist. If you have been well-controlled for an extended period on Q4W maintenance and would benefit from a less frequent injection schedule, this is a conversation worth initiating at your next dermatology appointment.

    For patients newly initiating Ebglyss: the standard induction and Q2W maintenance schedule remains the starting point. The Q8W option comes after achieving adequate clinical response, which typically occurs by week 16. The dosing path is: start with induction, achieve response, then discuss with your dermatologist whether Q4W or Q8W maintenance fits your response profile and lifestyle.

    For patients who have experienced significant conjunctivitis on dupilumab: lebrikizumab’s IL-13-only mechanism (not blocking IL-4) is associated with lower conjunctivitis rates than dupilumab in clinical trials, making it a clinically reasonable alternative for patients where ocular side effects have been a management challenge.

    For prescribers: the Q8W approval gives an additional tool for the conversation about long-term maintenance. Patient adherence to any chronic biologic therapy is improved by dosing schedules that fit into normal life rhythms. Six injections per year, administered at home without routine monitoring requirements, is a significantly lighter burden than monthly or biweekly regimens for patients who can achieve and sustain adequate disease control.

    For related HED coverage on biologics for inflammatory conditions and the expanding IL-13 inhibitor class, see our post on Fasenra (benralizumab) receiving its new indication for hypereosinophilic syndrome and our post on Xolair (omalizumab) and its biosimilar transition as part of the 2026 LOE series, which covers the broader IgE/type-2 inflammation treatment landscape in which both drug classes operate.

    Sources

    Lilly FDA approval press release: FDA approves Lilly’s EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks. Eli Lilly. investor.lilly.com. June 9, 2026.

    Drugs.com approval news: FDA Approves Lilly’s Ebglyss for One Maintenance Dose Every Eight Weeks. drugs.com. June 9, 2026.

    HCPLive clinical coverage: FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis. hcplive.com. June 2026.

    BioPharm International clinical coverage: FDA Approves Lebrikizumab Every-8-Week Maintenance Dosing for Moderate-Severe Atopic Dermatitis. biopharminternational.com. June 2026.

    Contemporary Pediatrics (with investigator caveat): FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis. contemporarypediatrics.com. June 2026.

    Dermatology Times coverage: Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD. dermatologytimes.com. June 2026.

    ADjoin extension (NCT04392154): NCT04392154. ClinicalTrials.gov.

    Silverberg J et al. (ADjoin Q8W data; Fall Clinical Dermatology Conference 2025): Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Fall Clinical Dermatology Conference. 2025.

    4-year durability data (Almirall): Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis. Almirall press release. March 27, 2026.

    Ebglyss original FDA approval (September 2024): FDA approves lebrikizumab-lbkz for atopic dermatitis. FDA.gov.

    Dupixent FDA approval: FDA approves dupilumab for moderate to severe atopic dermatitis. FDA.gov.

    Adbry FDA approval: FDA approves tralokinumab-ldrm for atopic dermatitis. FDA.gov.

    IL-13 in atopic dermatitis: IL-13 in Atopic Dermatitis. PMC8908499.

    Lebrikizumab IL-13 binding mechanism: Okragly A et al. Binding, neutralization and internalization of IL-13 antibody lebrikizumab. Dermatology and Therapy. 2023. doi:10.1007/s13555-023-00947-7.

    Lebrikizumab structural basis: Ultsch M et al. Structural basis of signaling blockade by IL-13 antibody lebrikizumab. Journal of Molecular Biology. 2013;425(8):1330-1339. doi:10.1016/j.jmb.2013.01.024.

    Atopic dermatitis epidemiology: Atopic Dermatitis. StatPearls. NCBI.

    Atopic dermatitis quality of life burden: AD Quality of Life and Burden. PMC7305275.

    NIAMS atopic dermatitis overview: Atopic Dermatitis. NIAMS.

    Ebglyss prescribing information: EBGLYSS (lebrikizumab-lbkz) Prescribing Information. Eli Lilly. 2026.

    Patient resources: National Eczema Association | American Academy of Dermatology: Find a Dermatologist | Lilly Ebglyss patient support

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about biologic therapy for atopic dermatitis, including the choice between Q4W and Q8W maintenance dosing for Ebglyss, should be made in close consultation with a board-certified dermatologist or allergist familiar with the patient’s disease history, prior treatment response, and overall health profile.
  • The Combination Acne Gel Dermatologists Have Prescribed for 15 Years Is Now Available Without a Prescription.

    The Combination Acne Gel Dermatologists Have Prescribed for 15 Years Is Now Available Without a Prescription.

    📌 The essentials On May 22, 2026, the FDA approved Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%, Galderma) for over-the-counter (OTC) use in adults and adolescents aged 12 years and older for the treatment of acne. This is a prescription-to-OTC switch. The product was previously available only with a dermatologist prescription. Retail availability: most major retailers including Walmart, Ulta, Target, and Amazon, beginning summer 2026. The clinical basis: more than 10 randomized, controlled Phase 3 clinical trials involving over 3,200 patients, plus more than 15 years of real-world prescription use. The combination gel consistently outperformed adapalene alone, benzoyl peroxide alone, and vehicle gel across inflammatory lesions, noninflammatory lesions, total lesion counts, and Investigator Global Assessment success rates. Inflammatory lesion reductions observed as early as week 1; up to 70.3% reduction in inflammatory lesions by week 12. Sustained efficacy demonstrated through 12 months of use. What makes this a meaningful access change: adapalene 0.1% plus benzoyl peroxide 2.5% is a guideline-recommended, first-line acne combination. Access was previously limited to patients with insurance coverage or the ability to afford a dermatology visit. This switch removes that barrier.

    Acne vulgaris is not a minor skin concern. It affects approximately 85% of people between ages 12 and 24 in the United States and persists into adulthood for a significant proportion. Beyond the physical manifestations, acne carries a well-documented psychological burden: studies consistently link moderate to severe acne with depression, anxiety, and reduced quality of life, particularly in adolescents and young adults. And yet, first-line prescription acne treatments have historically required an appointment with a dermatologist, a specialist with a median wait time of more than 30 days in many U.S. markets.

    The gap between when patients want treatment and when they can access effective treatment has been one of the persistent frustrations of acne care.

    On May 22, 2026, the FDA addressed one piece of that gap: it approved Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter use in patients aged 12 and older, making a combination that dermatologists have been prescribing for more than 15 years available at the drugstore without a visit to a clinic.

    This is not a watered-down consumer version of an effective drug. It is the same formulation, the same concentrations, and the same once-daily application that generated more than 10 randomized controlled trials and millions of prescriptions. The only thing that changed is that you no longer need a prescription to buy it.

    What Makes This Combination Different From Standard OTC Acne Products

    The drugstore acne aisle is full of products. Most of them contain one of three active ingredients: benzoyl peroxide, salicylic acid, or adapalene 0.1% (which became OTC in the United States in 2016). Understanding why the combination of adapalene and benzoyl peroxide is a step above either alone requires understanding what causes acne and what each ingredient addresses.

    The four drivers of acne vulgaris

    Acne is a multifactorial disease driven by four interconnected processes:

    Excess sebum production: The sebaceous glands produce more oil than the skin can manage, creating an environment that supports the growth of acne-causing bacteria.

    Follicular hyperkeratinization: Dead skin cells inside the hair follicle do not shed normally, causing the cells to accumulate and block the pore. This is what produces a comedone (clogged pore), which is the precursor to both whiteheads (closed comedones) and blackheads (open comedones).

    Propionibacterium acnes (now reclassified as Cutibacterium acnes) overgrowth: The bacteria that live on skin and inside follicles proliferate in the sebum-rich, low-oxygen environment of a blocked pore, triggering inflammatory responses.

    Inflammation: The immune system’s response to bacterial antigens inside the follicle produces the characteristic redness, swelling, and pain of inflammatory acne lesions (papules, pustules, nodules).

    No single-ingredient product addresses all four of these processes. This is precisely why dermatology guidelines have long recommended combination therapy as the standard of care.

    What adapalene does

    Adapalene is a third-generation synthetic retinoid developed by Galderma specifically to address the stability and tolerability limitations of earlier topical retinoids like tretinoin. Unlike tretinoin, adapalene is photostable and chemically stable, which matters for formulation: it can be combined with other active ingredients (including benzoyl peroxide) in a single product without degrading.

    Adapalene works at the cellular level by binding to specific retinoic acid receptors (RARs) in skin cells. By modulating gene expression in keratinocytes (the cells that line follicles), it normalizes the keratinization process, preventing the follicular plugging that leads to comedones. It also has direct anti-inflammatory activity. Adapalene is widely regarded as the best-tolerated topical retinoid available: it causes significantly less dryness, peeling, and redness than tretinoin at comparable efficacy, particularly early in treatment.

    What benzoyl peroxide does

    Benzoyl peroxide (BPO) is an oxidizing agent that releases free radicals in the skin, directly killing Cutibacterium acnes bacteria by degrading their cell membranes. It has been a cornerstone of acne therapy for decades. Critically, BPO does not cause bacterial resistance, unlike topical antibiotics such as clindamycin, where resistance has become a significant clinical problem. At 2.5%, the concentration in Differin Epiduo, research has shown comparable antibacterial efficacy to higher concentrations (5% and 10%) with a substantially better tolerability profile.

    Why the combination outperforms either ingredient alone

    The synergy between adapalene and BPO is mechanistic and well-documented. Adapalene normalizes follicular keratinization and reduces inflammation, creating a less obstructed skin environment. BPO eliminates the bacteria that drive inflammatory lesion development. Together, they address both the comedonal (non-inflammatory) and inflammatory components of acne through independent and complementary pathways.

    In multiple randomized controlled trials comparing adapalene/BPO gel to adapalene monotherapy, BPO monotherapy, and vehicle gel, the combination consistently outperformed all three comparators on every efficacy measure: inflammatory lesions, noninflammatory lesions, total lesions, and IGA success rates. The combination also produced faster onset, with lesion reductions detectable as early as week 1 of treatment.

    What the Investigator Global Assessment (IGA) measures The Investigator Global Assessment is the standard five-point scale used in acne clinical trials to assess overall acne severity: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. In clinical trials, an “IGA success” is typically defined as achieving a score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline. For most patients entering trials at IGA 3 (moderate), IGA success means moving from moderate acne to clear or almost-clear skin. This endpoint captures what patients actually care about: overall appearance, not just lesion counts. The combination adapalene/BPO gel achieved higher IGA success rates in pivotal trials than adapalene or BPO alone.

    The Clinical Evidence: More Than 10 Trials and 3,200 Patients

    The FDA’s approval of Differin Epiduo for OTC use is supported by one of the most extensive clinical evidence packages ever assembled for an acne product. Galderma cited more than ten Galderma-sponsored randomized controlled Phase 3 studies involving more than 3,200 patients, plus substantial third-party research, covering a wide range of ages, skin tones, and acne severity levels.

    The core efficacy story from that dataset:

    OutcomeResult (adapalene/BPO vs. vehicle)
    Inflammatory lesion reduction by week 12Up to 70.3% with combination vs. substantially lower with vehicle
    Noninflammatory lesion reduction by week 12Significant superiority over both monotherapies and vehicle
    IGA success rate (clear or almost clear)Higher with combination than adapalene alone, BPO alone, or vehicle
    Onset of efficacyDetectable as early as week 1
    DurabilitySustained efficacy demonstrated through 12 months
    Combination vs. adapalene aloneSuperior on inflammatory lesions, IGA success, total lesion count
    Combination vs. BPO aloneSuperior on noninflammatory lesions, IGA success, total lesion count

    Source: Galderma Phase 3 clinical program. Thiboutot DM et al. J Am Acad Dermatol. 2007. Multiple published trials. Presented by Galderma at FDA NDA and OTC switch submissions.

    The 70.3% reduction in inflammatory lesions at week 12 is a clinically significant number. Inflammatory lesions (papules, pustules) are the acne manifestations that cause pain, scarring risk, and the greatest psychosocial impact. Reducing them by nearly three-quarters over 12 weeks of once-daily application, at a concentration that is well tolerated, is what established this product as a first-line agent in dermatology practice.

    The long-term data through 12 months is particularly relevant for the OTC setting, where sustained use without continued prescriber oversight is the norm. The evidence indicates that the efficacy is maintained over months of use, not just in the initial weeks.

    Why Guideline-Concordant Acne Treatment Has Been Inaccessible

    The American Academy of Dermatology (AAD) guidelines for acne and the Global Alliance to Improve Outcomes in Acne both recommend topical retinoid plus benzoyl peroxide combinations as a first-line, guideline-preferred approach for mild to moderate acne. Adapalene/BPO is specifically named in clinical guidelines as a preferred dual-active regimen.

    Despite this guideline support, the combination has been behind the prescription barrier until now. This matters for several overlapping reasons.

    Dermatologist access: An estimated one-third of Americans lack access to a dermatologist within a reasonable distance from their home. Rural and underserved urban areas are particularly affected. Patients in these areas have historically been limited to products available OTC, which until this approval did not include a retinoid/BPO combination at guideline-recommended concentrations.

    Cost of care: A dermatology visit for acne, without insurance coverage, typically runs $100 to $250 for an initial consultation. For uninsured or underinsured adolescents and young adults, this is a significant barrier. Prescription co-pays for Epiduo with insurance have historically ranged widely, and without insurance, the prescription price could run over $200 per tube.

    Prescription gap for patients who improve: Even patients who see a dermatologist and get a prescription face ongoing friction: refill appointments, pharmacy trips, and the possibility of insurance changes affecting coverage. OTC availability removes these recurring barriers for sustained use.

    The skin tone gap in acne care: Post-inflammatory hyperpigmentation (PIH), the dark marks left after acne lesions resolve, is more prevalent and more severe in patients with darker skin tones. Adapalene has documented evidence of reducing PIH as part of its normalization of cell turnover, making consistent access to a retinoid-containing product particularly meaningful for patients with skin of color who experience this complication disproportionately.

    The Prescription-to-OTC Switch Process: What the FDA Reviews

    A prescription-to-OTC switch is not simply a label change. It requires a separate FDA regulatory review demonstrating that:

    • The drug can be used safely and effectively by consumers without physician supervision
    • The indication, dosing instructions, and labeling are understandable to lay consumers
    • The drug’s benefits outweigh its risks in the self-use context
    • Long-term safety data support unsupervised use

    The FDA’s review of the Differin Epiduo OTC switch drew on more than 15 years of prescription use safety data, a global safety database including millions of prescriptions, and the consumer use clinical program. The approval for ages 12 and older reflects confidence that the product can be used safely and effectively by adolescents as well as adults in a self-directed context.

    How to Use Differin Epiduo: What the Label Covers

    Differin Epiduo Acne Gel is intended for once-daily use, applied as a thin layer to the entire acne-affected area, not just to individual spots. This is an important and commonly misunderstood instruction: spot-treating active lesions misses the comedonal component of acne developing just below the surface.

    Key application instructions:

    • Apply a thin layer to the affected area once daily in the evening, after washing and gently drying the skin
    • Use your fingertips to apply a pea-sized amount for the entire face; a larger amount for the back, chest, or other areas
    • Wash hands immediately after applying
    • Allow to dry completely before applying moisturizer or other products on top
    • Avoid contact with eyes, lips, and mucous membranes; if contact occurs, rinse thoroughly with water

    What to expect:

    Weeks 1 to 4 often bring a temporary “adjustment period” of mild skin dryness, redness, or peeling as the skin adapts to retinoid use. This is normal and typically resolves with continued use. Starting with every-other-day application for the first 1 to 2 weeks can reduce early irritation.

    Sun protection: Adapalene-containing products increase photosensitivity. Use broad-spectrum SPF 30 or higher sunscreen daily during treatment and limit sun exposure. Do not apply immediately before sun exposure.

    Moisturizer: Using a non-comedogenic moisturizer daily helps manage dryness and improve tolerability, especially during the adjustment period.

    Warnings and who should not use it

    • Do not use if you are allergic to adapalene or benzoyl peroxide
    • Avoid contact with bleachable fabrics (towels, pillowcases, clothing): benzoyl peroxide bleaches fabric
    • Discontinue and consult a healthcare provider if severe irritation, allergic reaction, or significant worsening occurs
    • Pregnancy: adapalene is in FDA pregnancy category C for topical use. Animal data suggests potential risk. The systemic absorption from topical application is minimal, but out of an abundance of caution, consult a healthcare provider before use during pregnancy or breastfeeding
    • For the youngest eligible users (ages 12 to 15): a parent or guardian should supervise initial use to ensure correct application technique and sun protection compliance

    Where Differin Epiduo Fits in the OTC Acne Landscape

    Until this approval, the OTC landscape for combination acne therapy was limited. Here is how Differin Epiduo compares to what was already available:

    OTC product typeActive ingredientsMechanismGuideline status
    Benzoyl peroxide alone (2.5%, 5%, 10%)BPOAntimicrobialGuideline-recommended; available OTC for decades
    Salicylic acid (0.5% to 2%)Beta-hydroxy acidMild keratolyticUseful for mild comedonal acne; less evidence for inflammatory lesions
    Adapalene 0.1% gel (Differin)AdapaleneRetinoidGuideline-recommended; OTC since 2016
    Differin Epiduo Acne Gel (new)Adapalene 0.1% plus BPO 2.5%Retinoid plus antimicrobialGuideline-recommended first-line combination; now OTC

    The arrival of the combination gel completes the adapalene-based OTC acne care ladder: monotherapy adapalene 0.1% for mild comedonal acne, combination adapalene/BPO 0.1/2.5% for mild to moderate inflammatory and mixed acne, and a dermatologist pathway for severe, nodular, or treatment-resistant disease.

    For Patients: Practical Guidance

    This product is appropriate for:

    • Adults and adolescents aged 12 and older with mild to moderate acne, including both inflammatory (red, swollen pimples) and non-inflammatory (blackheads, whiteheads) lesions
    • People who have not had success with single-ingredient products
    • People who previously used Epiduo by prescription and want to continue without the prescription barrier
    • People who want a guideline-concordant first-line treatment without a clinic visit

    This product is not appropriate as a standalone treatment for:

    • Nodular or cystic acne (large, deep, painful lesions), which requires dermatologist care
    • Severe acne with significant scarring risk
    • Acne unresponsive to OTC treatment after 12 weeks of consistent use

    When to see a dermatologist: If your acne has not improved after 12 weeks of consistent daily use, if you develop nodules or cysts, if you have significant post-inflammatory dark marks (hyperpigmentation) that are not improving, or if your acne is causing significant psychological distress, a dermatology consultation is appropriate. The AAD’s Find a Dermatologist tool can help locate a board-certified dermatologist. For those with limited access to in-person care, several telehealth dermatology platforms provide prescription acne treatment via video or asynchronous consultation.

    For a related HED post covering the icotrokinra (ICOTYDE) approval as another step toward effective skin condition treatment options, see our post on the first oral IL-23 receptor blocker for psoriasis.

    Sources

    FDA approval news: FDA Approves Differin Epiduo Acne Gel (adapalene/benzoyl peroxide) for Nonprescription Use in the Treatment of Acne. Drugs.com. May 24, 2026.

    Galderma press release: Galderma Receives U.S. FDA Approval for Differin Epiduo Acne Gel Prescription-to-OTC Switch. businesswire.com. May 22, 2026.

    Galderma website announcement: Galderma Receives U.S. FDA Approval for Differin Epiduo Acne Gel Prescription-to-OTC Switch. galderma.com. May 22, 2026.

    Practical Dermatology clinical coverage: FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gel. practicaldermatology.com. May 2026.

    The Dermatology Digest clinical coverage: US FDA Approves Prescription-to-OTC Switch for Differin Epiduo Acne Gel. thedermdigest.com. May 2026.

    Drugs.com approval history: Differin Epiduo Acne Gel FDA Approval History. drugs.com.

    Pivotal combination trial (JAAD 2007): Thiboutot DM et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007.

    AAD acne guidelines: American Academy of Dermatology. Guidelines of care for the management of acne vulgaris. aad.org.

    Acne biology and pathophysiology: Acne Vulgaris. StatPearls. NCBI.

    Adapalene mechanism: Adapalene. StatPearls. NCBI.

    Benzoyl peroxide mechanism: Benzoyl Peroxide. StatPearls. NCBI.

    Retinoid receptor biology: Retinoids in Dermatology. PMC4756869.

    IGA scale validation: Investigator Global Assessment in Acne. PMC5300780.

    Global Alliance acne guidelines: Global Alliance to Improve Outcomes in Acne. PMC7374761.

    Patient resources: AAD: What Is Acne? | AAD Find a Dermatologist | National Eczema Association (for skin barrier support)

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Patients with severe, nodular, or cystic acne, those who are pregnant or breastfeeding, and those whose acne does not respond to OTC treatment after 12 weeks should consult a board-certified dermatologist.